Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Outcomes and clinical implications of intranasal insulin administration to the central nervous system.

Santiago JCP, Hallschmid M.

Exp Neurol. 2019 Mar 15. pii: S0014-4886(18)30598-3. doi: 10.1016/j.expneurol.2019.03.007. [Epub ahead of print] Review.

PMID:
30885653
2.

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.

Mousa SA, Ayoub BM.

Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217. Review.

3.

Efficacy of Intranasal Insulin in Improving Cognition in Mild Cognitive Impairment and Alzheimer Disease: A Systematic Review and Meta-analysis.

Lu J, Xu Z.

Am J Ther. 2019 Jan 3. doi: 10.1097/MJT.0000000000000926. [Epub ahead of print] No abstract available.

PMID:
30648990
4.

Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice.

Gabbouj S, Natunen T, Koivisto H, Jokivarsi K, Takalo M, Marttinen M, Wittrahm R, Kemppainen S, Naderi R, Posado-Fernández A, Ryhänen S, Mäkinen P, Paldanius KMA, Doria G, Poutiainen P, Flores O, Haapasalo A, Tanila H, Hiltunen M.

Neurobiol Aging. 2019 Mar;75:98-108. doi: 10.1016/j.neurobiolaging.2018.11.008. Epub 2018 Nov 17.

5.

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome.

Tramutola A, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L, Blarzino C, Butterfield DA, Perluigi M, Di Domenico F.

Transl Neurodegener. 2018 Nov 6;7:28. doi: 10.1186/s40035-018-0133-9. eCollection 2018.

6.

Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice.

Li X, Run X, Wei Z, Zeng K, Liang Z, Huang F, Ke D, Wang Q, Wang JZ, Liu R, Zhang B, Wang X.

Curr Alzheimer Res. 2019;16(1):8-18. doi: 10.2174/1567205015666181031145045.

PMID:
30381076
7.

Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease.

Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, Gaetani S, Grassi C, Butterfield DA, Cassano T, Perluigi M.

Mol Neurobiol. 2018 Aug 2. doi: 10.1007/s12035-018-1231-5. [Epub ahead of print]

PMID:
30073505
8.

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.

Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS.

Diabetes Obes Metab. 2018 Oct;20(10):2467-2471. doi: 10.1111/dom.13373. Epub 2018 Jun 19. Review.

PMID:
29790638
9.

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A.

J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24. Review.

PMID:
29772289
10.

Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease.

Duarte AI, Santos MS, Oliveira CR, Moreira PI.

Neuropharmacology. 2018 Jul 1;136(Pt B):223-242. doi: 10.1016/j.neuropharm.2018.01.044. Epub 2018 Feb 20. Review.

PMID:
29471055
11.

Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Avgerinos KI, Kalaitzidis G, Malli A, Kalaitzoglou D, Myserlis PG, Lioutas VA.

J Neurol. 2018 Jul;265(7):1497-1510. doi: 10.1007/s00415-018-8768-0. Epub 2018 Feb 1. Review.

PMID:
29392460
12.

Nose-to-brain delivery of insulin enhanced by a nanogel carrier.

Picone P, Sabatino MA, Ditta LA, Amato A, San Biagio PL, Mulè F, Giacomazza D, Dispenza C, Di Carlo M.

J Control Release. 2018 Jan 28;270:23-36. doi: 10.1016/j.jconrel.2017.11.040. Epub 2017 Dec 2.

PMID:
29196041
13.

Intranasal insulin in Alzheimer's disease: Food for thought.

Chapman CD, Schiöth HB, Grillo CA, Benedict C.

Neuropharmacology. 2018 Jul 1;136(Pt B):196-201. doi: 10.1016/j.neuropharm.2017.11.037. Epub 2017 Nov 24. Review.

14.

Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia.

Kamei N.

Yakugaku Zasshi. 2017;137(10):1247-1253. doi: 10.1248/yakushi.17-00138. Review. Japanese.

15.

Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer's Rat Model.

Chen Y, Guo Z, Mao YF, Zheng T, Zhang B.

Neurotox Res. 2018 May;33(4):716-724. doi: 10.1007/s12640-017-9809-7. Epub 2017 Sep 19.

PMID:
28929339
16.

Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.

Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR.

J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21.

PMID:
28870559
17.
18.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

19.

Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease.

Kang S, Lee YH, Lee JE.

Yonsei Med J. 2017 May;58(3):479-488. doi: 10.3349/ymj.2017.58.3.479. Review.

20.

Clinical Aspects of Glucose Metabolism and Chronic Disease.

Culberson JW.

Prog Mol Biol Transl Sci. 2017;146:1-11. doi: 10.1016/bs.pmbts.2016.12.011. Epub 2017 Feb 1. Review.

PMID:
28253982

Supplemental Content

Loading ...
Support Center